CKD Bio Corp.

A063160

KR7063160006

Pharmaceuticals

End-of-day quote Korea S.E. Other stock markets 23:00:00 15/05/2024 BST			5-day change	1st Jan Change
24,100 ^KRW	-0.62%		+0.42%	+1.05%

2023	CKD Bio Corp. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	CI
2023	CKD Bio Corp.(KOSE:A063160) dropped from S&P Global BMI Index	CI

CKD Bio Corp.(KOSE:A063160) added to S&P Global BMI Index

September 21, 2020 at 05:00 am

Latest news about CKD Bio Corp.

CKD Bio Corp. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-14	CI
CKD Bio Corp.(KOSE:A063160) dropped from S&P Global BMI Index	18/09/23	CI
CKD Bio Corp. Reports Earnings Results for the First Quarter Ended March 31, 2023	15/05/23	CI
CKD Bio Corp. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	14/11/22	CI
CKD Bio Corp. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	16/08/22	CI
CKD Bio Corp. Reports Earnings Results for the First Quarter Ended March 31, 2022	16/05/22	CI
CKD Bio Corp. Reports Earnings Results for the Full Year Ended December 31, 2021	17/03/22	CI
CKD Bio Corp. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2021	15/11/21	CI
Exclusive: South Korea's GL Rapha to ship out 10 million Sputnik Light COVID-19 shots this month	14/09/21	RE
Boryung Pharmaceutical : S.Korea's GL Rapha to ship out 10 mln Sputnik Light COVID-19 shots this month	14/09/21	RE
CKD Bio Corp.(KOSE:A063160) added to S&P Global BMI Index	21/09/20	CI
Chong Kun Dang Holdings Corp. completed the acquisition of additional 35.67% stake in Ckd Bio Corporation for KRW 61.6 billion.	11/07/16	CI
Chong Kun Dang Holdings Corp. made an offer to acquire an additional 35.67% stake in Ckd Bio Corporation for KRW 55.9 billion.	18/05/16	CI
Korea Securities Finance Corporation acquired 4.11% stake in Ckd Bio Corporation.	09/01/15	CI
Ckd Bio Corporation Announces Earnings Results for the Full Year Ended December 31, 2012	19/05/13	CI

CKD Bio Corp. is a Korea-based company specialized in the manufacturing of pharmaceutical products. The Company mainly provides antibiotic ingredients, consisting of demethylchlortetracyclines (DMCTs) and rifampicins. It also provides immunosuppressive agents, including cyclosporin and tacrolimus; remedies for diabetes, such as acarbose, and potassium clavulanate used for beta-lactam inhibitors. The Company distributes its products within domestic market and to overseas markets, such as America, China, Europe, Africa, Southeast Asia, Latin America and the Middle East.

Sector

Pharmaceuticals

Calendar

12/08/2024 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Sector Other Pharmaceuticals

	1st Jan change	Capi.
CKD BIO CORP.	+1.05%	98.15M
ELI LILLY AND COMPANY	+32.75%	694B
NOVO NORDISK A/S	+29.39%	593B
JOHNSON & JOHNSON	-1.59%	371B
MERCK & CO., INC.	+20.09%	331B
ABBVIE INC.	+6.60%	290B
ASTRAZENECA PLC	+14.06%	239B
ROCHE HOLDING AG	-3.15%	209B
NOVARTIS AG	+9.91%	209B
AMGEN INC.	+8.13%	169B